4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET In this webinar we: • Highlight the results of the research • Expand on the datapackage used • Discuss the gap between EU and US IP productivity in healthcare • Address the need for IP in the global biotech sector
Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP. This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.
DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies
24th June 2018, Boston, USA
Duane Schulthess, Managing Director of Vital Transformation, and Luca Pani, former Director General of the Italian Medicine's Agency and currently a Faculty Member at the University of Miami, will run a 3 hour and 15 minute Short Course outlining how best to harness RWE to better understand the price, value, and impact of next generation therapies.
The Alliance for Regenerative Medicine (ARM) supports the efforts of the Better Science Better Health IP Consortium
ARM is the leading international advocacy organization representing the gene and cell therapy sector and consists of more than 290 members, including life sciences companies, patient advocacy groups, academic research institutions, and investors.
Digital Citizen, Digital Patient: Estonia’s upcoming – first-ever – EU Presidency will put eHealth high on the agenda
An interview with Ain Aaviksoo, Deputy General Secretary on eServices and Innovation, Ministry of Social Affairs, Estonia.
A key aim of the Presidency is to promote Digital Europe. In eHealth the goal will be to highlight how digital technologies can contribute to the sustainability and resilience of healthcare systems.
Vital Transformation recently interviewed TiGenix CEO Eduardo Bravo and President of the European Biopharmaceutical Enterprises (EBE) on the implications of this lack of liquidity in Europe.
Register now to receive all the latest news and events.
Our consultancy services
30th December, 2017
Visit our youtube channel to view all of our videos.